Effect of RNA-Seq data normalization on protein interactome mapping for Alzheimer's disease.

Comput Biol Chem

Department of Bioengineering, Gebze Technical University, Gebze, Kocaeli, 41400, Turkey. Electronic address:

Published: April 2024

High throughput RNA sequencing brings new perspective to the elucidation of molecular mechanisms of diseases. Normalization is the first and most important step for RNA-Seq data, and it can differ based on the purpose of the analysis. Within-sample normalization methods (eg. TPM) are preferred when genes in a sample are compared with each other, and between-sample normalization methods (eg. deseq2, TMM, Voom) are used when the samples in a dataset are compared. Normalization approaches rescale the data, and, therefore, they affect the results of the analysis. Here, we selected two most commonly used Alzheimer's disease RNA-Seq datasets from ROSMAP and Mayo Clinic cohorts and mapped the differentially expressed genes on human protein interactome to discover disease-specific subnetworks. To this end, the raw count data were first processed with four different, commonly used RNA-Seq normalization methods (deseq2, TMM, Voom and TPM). Then, covariate adjustment was applied to the normalized data for gender, age of death and post-mortem interval. Each normalized dataset was separately mapped on the human protein-protein interaction network either in covariate-adjusted or non-adjusted form. Capturing known Alzheimer's disease genes and genes associated with the disease-related functional terms in the discovered subnetworks were the criteria to compare different normalization methods. Based on our results, applying covariate adjustment has a positive effect on normalization by removing the confounder effects. Covariate-adjusted TMM and covariate-adjusted deseq2 methods performed better in both transcriptome datasets.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.compbiolchem.2024.108028DOI Listing

Publication Analysis

Top Keywords

normalization methods
16
alzheimer's disease
12
rna-seq data
8
normalization
8
protein interactome
8
methods deseq2
8
deseq2 tmm
8
tmm voom
8
covariate adjustment
8
methods
5

Similar Publications

Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Imperial College London, London, United Kingdom; Division of Neurology, Department of Brain Sciences, Imperial College London, United Kingdom, London, London, United Kingdom.

Background: Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue licensed for the treatment of type 2 diabetes mellitus (T2DM). Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells.

Method: This is a multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild to moderate Alzheimer's dementia, conducted at several centres in the UK.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Patiala, India.

Background: Neuroinflammation plays an important role in progression of Alzheimer's disease (AD). Interlukin-6 (IL-6) is well identified marker in initiating and regulating inflammation, and formation of senile plaques in brain. Therefore, simultaneous inhibition of both IL-6 and acetylcholinesterase (AChE) may be an effective strategy for AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Actinogen Medical, Sydney, Australia.

Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: The ability to monitor cognitive trajectories over the course of trials can provide valuable insights into treatment efficacy. However, existing trial methods are limited in monitoring cognition in real-time and at high frequencies. Gameplay-based assessments hold promise as complementary cognitive tools.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!